Earnings Feed
Start Free
Home/Filings/4/0001354488-14-001399
4//SEC Filing

PERNIX THERAPEUTICS HOLDINGS, INC. 4

Accession 0001354488-14-001399

CIK 0001024126operating
View on SEC.govCompany Profile

Filed

Mar 24, 8:00 PM ET

Accepted

Mar 25, 5:16 PM ET

Size

37.3 KB

Accession

0001354488-14-001399

Insider Transaction Report

Form 4
Period: 2014-03-03
PERNIX THERAPEUTICS HOLDINGS, INC.PTX
Smith James Edward Jr.
Director10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-13$3.68/sh−15,000$55,157→ 4,867,704 total
  • Sale

    Common Stock

    2014-03-19$4.75/sh−15,000$71,253→ 4,807,704 total
  • Sale

    Common Stock

    2014-03-21$5.51/sh−15,000$82,620→ 4,777,704 total
  • Sale

    Common Stock

    2014-03-11$3.78/sh−15,000$56,663→ 4,897,704 total
  • Sale

    Common Stock

    2014-03-14$3.63/sh−15,000$54,522→ 4,852,704 total
  • Sale

    Common Stock

    2014-03-24$5.71/sh−15,000$85,580→ 4,762,704 total
  • Sale

    Common Stock

    2014-03-03$3.59/sh−15,000$53,807→ 4,987,704 total
  • Sale

    Common Stock

    2014-03-06$3.70/sh−15,000$55,551→ 4,942,704 total
  • Sale

    Common Stock

    2014-03-07$3.68/sh−15,000$55,227→ 4,927,704 total
  • Sale

    Common Stock

    2014-03-10$3.70/sh−15,000$55,496→ 4,912,704 total
  • Sale

    Common Stock

    2014-03-18$4.32/sh−15,000$64,839→ 4,822,704 total
  • Sale

    Common Stock

    2014-03-25$5.73/sh−15,000$85,946→ 4,747,704 total
  • Sale

    Common Stock

    2014-03-04$3.57/sh−15,000$53,492→ 4,972,704 total
  • Sale

    Common Stock

    2014-03-05$3.57/sh−15,000$53,513→ 4,957,704 total
  • Sale

    Common Stock

    2014-03-12$3.66/sh−15,000$54,873→ 4,882,704 total
  • Sale

    Common Stock

    2014-03-17$3.62/sh−15,000$54,369→ 4,837,704 total
  • Sale

    Common Stock

    2014-03-20$5.31/sh−15,000$79,593→ 4,792,704 total
Holdings

  • Common Stock

    (indirect: By daughter)
    3,200
Footnotes (18)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/3/14.
  • [F10]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.76, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F11]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.66, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F12]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.54 to $3.75, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F13]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.60, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F14]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.44 to $4.94, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F15]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 to $5.52, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F16]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.96, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F17]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.95, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F18]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $5.85, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.46 to $3.74, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $_____ to $_____, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.49 to $3.68, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.54 to $3.81, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F6]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.73, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F7]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.78, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F8]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.92, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F9]The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.74, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file

Issuer

PERNIX THERAPEUTICS HOLDINGS, INC.

CIK 0001024126

→
Entity typeoperating
IncorporatedMD

Related Parties

1
  • filerCIK 0001024126

Filing Metadata

Form type
4
Filed
Mar 24, 8:00 PM ET
Accepted
Mar 25, 5:16 PM ET
Size
37.3 KB
View on SEC.gov